Scientists uncover clues to inflammation in rare bone marrow disease

NCT ID NCT07319026

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 70 people—some with primary myelofibrosis and some healthy—to understand how certain immune cells called MDSCs fuel inflammation in this rare bone marrow disease. Researchers also checked how these cells change with treatment and whether they help form new blood vessels. The goal is to find new targets for future therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    Pavia, Italy, 27100, Italy